Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 9/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31388377 | 0.88 | MAPT (0.64) | KDM4ENPC1RAB9AALDH1A1SLC16A3 | |
| SCHEMBL2389126 | 0.88 | MAPT (0.64) | KDM4ENPC1RAB9AALDH1A1SLC16A3 | |
| SCHEMBL4505226 | 0.84 | MAPT (0.69) | KDM4ENPC1RAB9AALDH1A1SLC16A3 | |
| SCHEMBL25997308 | 0.82 | MAPT (0.44) | KDM4ENPC1RAB9AALDH1A1CASP3 | |
| SCHEMBL25997312 | 0.82 | MAPT (0.42) | KDM4ENPC1RAB9AALDH1A1CASP3 | |
| SCHEMBL20917468 | 0.82 | KDM4E (0.51) | KDM4ENPC1RAB9AALDH1A1CASP3 | |
| SCHEMBL30165796 | 0.82 | KDM4E (0.51) | KDM4ENPC1RAB9AALDH1A1CASP3 | |
| SCHEMBL25997345 | 0.81 | AGPAT2 (0.53) | KDM4ENPC1RAB9AALDH1A1CASP3 | |
| SCHEMBL11210328 | 0.81 | MAPT (0.63) | KDM4ENPC1RAB9AALDH1A1CASP3 | |
| SCHEMBL22371414 | 0.81 | MAPT (0.47) | KDM4ENPC1RAB9AALDH1A1SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050169837-A1 | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-08-04 | — | — | US | claimed |
| CN-1628114-A | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-06-15 | — | — | CN | claimed |
| EP-1483262-A1 | COUMARINES USEFUL AS BIOMARKERS | Novartis AG (CH) | 2004-12-08 | — | — | EP | claimed |
| WO-2003074519-A1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2003-09-12 | — | — | WO | claimed |
| US-RE47689-E1 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2797592-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2015095449-A1 | METHODS FOR MODULATING THE AMOUNT RNA TRANSCRIPTS | PTC THERAPEUTICS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-7569337-B2 | Labeling brain tissues in vivo or in vitro; 3-Benzothiazol-2-yl-7-[4-(2-fluoro-ethyl)-piperazin-1-yl]-chromen-2-one; diagnosis, monitoring the effectiveness of a therapeutic treatment and detecting histopathological hallmarks of Alzheimer's disease | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| US-20050169837-A1 | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-08-04 | — | — | US | disclosed |
| CN-1628114-A | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-06-15 | — | — | CN | disclosed |
| EP-1483262-A1 | COUMARINES USEFUL AS BIOMARKERS | Novartis AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074519-A1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050169837-A1 | Coumarines useful as biomarkers | CCNB1, CBR1, CYP1A1 | KDM4E 2497/4885NPC1 492/4885RAB9A 2178/4885 |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, RBM17, RBM22 | KDM4E 829/4885NPC1 4329/4885RAB9A 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.